Alcohol Induced Depression: Clinical, Biological and Genetic Features
| Autor: | Adriana Farré, Marta Torrens, Francina Fonseca, Nino Spataro, María Alías-Ferri, Judit Tirado |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Medicine 030508 substance abuse Genome-wide association study Alcohol use disorder alcohol use disorder primary major depression Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Blood test GWAS Family history clinical characteristics Depression (differential diagnoses) medicine.diagnostic_test alcohol induced major depression business.industry lcsh:R Anhedonia biomarkers Clinical characteristics comorbidity General Medicine medicine.disease Comorbidity 3. Good health Anxiety medicine.symptom 0305 other medical science business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Clinical Medicine; Volume 9; Issue 8; Pages: 2668 Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 2668, p 2668 (2020) |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm9082668 |
| Popis: | Background: In clinical practice, there is the need to have clinical and biological markers to identify induced depression. The objective was to investigate clinical, biological and genetic differences between Primary Major Depression (Primary MD) and Alcohol Induced MD (AI-MD). Methods: Patients, of both genders, were recruited from psychiatric hospitalisation units. The PRISM instrument was used to establish the diagnoses. Data on socio-demographic/family history, clinical scales for depression, anxiety, personality and stressful life events were recorded. A blood test was performed analysing biochemical parameters and a Genome Wide Association Study (GWAS) to identify genetic markers associated with AI-MD. Results: A total of 80 patients were included (47 Primary MD and 33 AI-MD). The AI-MD group presented more medical comorbidities and less family history of depression. There were differences in traumatic life events, with higher scores in the AI-MD (14.21 ± 11.35 vs. 9.30 ± 7.38; p = 0.021). DSM-5 criteria were different between groups with higher prevalence of weight changes and less anhedonia, difficulties in concentration and suicidal thoughts in the AI-MD. None of the genetic variants reached significance beyond multiple testing thresholds; however, some suggestive variants were observed. Conclusions: This study has found clinical and biological features that may help physicians to identify AI-MD and improve its therapeutic approach. This project has received funding from the European Union’s Horizon 2020 research and innovation programme 2014–2020 under Grant Agreement No. 634143 (MedBioinformatics) and ISCIII-Red de Trastornos Adictivos-RTA-FEDER (RD12/0028/0009 and RD16/0017/0010). Acció instrumental d’Intensificació de Professionals de la Salut—Facultatius especialistes (PERIS: SLT006/17/00014). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |